Skip to main content
. 2017 Aug 7;19(6):577–593. doi: 10.1007/s40272-017-0251-3

Table 6.

Reported late effects in patients with stage 4 disease aged >18 months surviving ≥1 year after diagnosis

Trial NB79 NB82 NB85 NB90 NB97 NB04 All
N 46 47 91 235 250 364 1019
Renal impairment 0 2.1 4.4 19.6 13.2 4.7 9.9
Thyroid dysfunction 0 0 3.3 4.7 10 16.2 9.6
Hearing loss 0 0 1.1 3.8 8.4 10.2 6.7
Second malignancya 0 0 1.1 8.9 1.2 1.9 3.1
Growth retardation 0 4.3 2.2 4.7 2 1.9 2.6
Hepatopathy 0 0 0 3 1.6 4.1 2.6
Spine deformaties 0 0 2.2 4.7 1.6 0.8 2
Cardiovascular dysfunction 0 2.1 1.1 2.1 1.6 0.8 1.4
Peripheral neuropathy 0 0 0 0.4 0.8 0.5 0.5

Data are presented as %

aSecond malignancies without time restrictions: any time after diagnosis (median time of observed cases 70 months, minimum 12 months, maximum 253 months)